TD Cowen Sticks with Buy Rating on Amgen Amid Strong Growth Prospects
TD Cowen analyst Yaron Werber has reaffirmed his buy rating for biotech giant Amgen (AMGN.US), maintaining a target price of $452. This decision comes after analyzing Amgen's performance and potential growth prospects.
In accordance with data from TipRanks, Werber boasts a success rate of 62.5% and an average return of 30.7% over the past year. The analyst's track record is evaluated on a scale of 1 to 5 stars by TipRanks, which currently assigns him 4 out of 5 stars based on his performance.
It's worth noting that Werber's buy rating and target price for Amgen remain unchanged from previous recommendations, indicating confidence in the company's future prospects. As always, investors are advised to conduct their own research and consider multiple sources before making investment decisions.